Related Experiment Video

Updated: Jul 7, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

2-Methoxyestradiol and multidrug resistance: can 2-methoxyestradiol chemosensitize resistant breast cancer cells?

Samar S Azab1, Salama A Salama, Ashraf B Abdel-Naim

  • 1Department of Obstetrics and Gynecology, University of Texas-Medical Branch, Galveston, TX, USA.

Breast Cancer Research and Treatment
|January 30, 2008
PubMed

Insights

2-Methoxyestradiol (2ME) enhances doxorubicin (Dox) effectiveness against multidrug-resistant breast cancer cells. This study reveals 2ME downregulates Bcl2 and Cyclin D1, boosting cancer cell death and cell cycle arrest.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Breast cancer often develops resistance to chemotherapy, limiting treatment efficacy.
  • Multidrug resistance (MDR) is a significant challenge in treating breast cancer, necessitating novel therapeutic strategies.
  • 2-Methoxyestradiol (2ME), an estradiol derivative, is under investigation for its anti-cancer properties.

Purpose of the Study:

  • To investigate the modulatory effects of 2ME on multidrug resistance (MDR) in doxorubicin (Dox)-resistant breast cancer cells (MCF-7/Dox).
  • To elucidate the underlying molecular mechanisms by which 2ME influences Dox sensitivity and resistance.
  • To evaluate the chemosensitizing potential of 2ME in combination with Dox therapy.

Main Methods:

  • MTT assay was employed to determine the chemosensitizing effect of 2ME on Dox cytotoxicity.
  • RT(2) Profiler PCR Array and Western blotting were used to analyze the expression of key genes (MDR1, Bcl2, P53, Cyclin D1).
  • Functional assays included p-glycoprotein (p-gp) function, caspase 3 activity, and flowcytometric cell cycle analysis.

Main Results:

  • 2ME significantly increased the sensitivity of MCF-7/Dox cells to Dox by 2.9-fold.
  • Gene expression analysis revealed downregulation of Bcl2 and Cyclin D1, with no significant change in P53, and overexpression of MDR1 upon combined treatment.
  • 2ME enhanced p-gp function by 24%, increased caspase 3 activity by 27-fold, and induced cell cycle arrest in G1 and S phases.

Conclusions:

  • 2ME effectively chemosensitizes multidrug-resistant breast cancer cells to Dox.
  • The mechanism involves downregulation of Bcl2 and Cyclin D1, augmentation of caspase 3 activity, and induction of cell cycle arrest.
  • 2ME represents a promising agent for overcoming Dox resistance in breast cancer treatment.

More Related Videos

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...